Recent studies have shown that immune cells can drive important clinical features that affect breast cancer treatment outcomes, especially for the more aggressive proliferative subtypes of breast cancer, such as triple-negative breast cancer (TNBC) and HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.